ABBOTT fait son marché ....chronic pain drug ,early stage

Abbott buys pain drug candidate for up to $190M




NORTH CHICAGO, Ill. — Abbott Laboratories said Thursday it is buying
a potential chronic pain drug from PanGenetics BV for as much as $190
million.Abbott said the drug is in early-stage clinical testing
as a treatment for pain cause by arthritis. If that trial is
successful, Abbott may test it against chronic lower back pain, cancer
pain, and diabetic nerve pain. It said the drug blocks a chemical
called nerve growth factor, or NGF, which is released at sites where
tissues are damaged or inflamed.PanGenetics, based in the
Netherlands, will receive $170 million upfront from Abbott, and $20
million in milestone payments if the drug advances through development.
Abbott said the deal will close before the end of 2009, and while it
will take one-time charges related to the deal, the company said it
does not need to change its profit guidance for the year.In morning trading, Abbott stock rose a penny to $53.27.


rappel ...abbott une des favorites de sebi pour partenariat

NEW YORK (Reuters) - Fred Hassan, former head of Schering-Plough Corp, said Merck & Co (MRK.N: Quote, Profile, Research, Stock Buzz) is likely to prevail over Johnson & Johnson (JNJ.N: Quote, Profile, Research, Stock Buzz) in its battle to retain overseas rights to the blockbuster arthritis drug Remicade.


"Personally, I feel good that Merck will be able to keep Remicade,"
Hassan said on Thursday at the Reuters Health Summit in New York, just
four weeks after completing the $41 billion sale of his company to
Merck.


Schering-Plough garnered $2 billion a year in overseas sales of
Remicade under a long-term marketing pact with J&J. The deal
required Schering-Plough to hand back the sales rights if it underwent
a change of control.


But that requirement became clouded when the Schering-Plough/Merck
deal was structured as a reverse merger -- which technically means
Schering-Plough bought the larger company even though the combined
company retained the Merck name and Merck's CEO.


J&J objected to the reverse-merger logic. An arbitrator is expected to decide the high-stakes matter.


"We had very good external advice; the case is good," Hassan said.

Merci.
C'est un Tanezumab bis apparemment (donc peut-être aussi en injections intraveineuses) qui vient de seulement de commencer une phase I.

mais cela donne une idée des deals possibles et qui plus est en phase I, encore.
Sur un secteur de vente qui est loin d'atteindre les ventes du Lipitor (12.9Mds$)
ni son marché 25mds$ anticipé.

Pour ne parler que du NCX 6560.

Bref on nous disait les big pharma sclérosées apres les Fusions.
Certaines dégaines pourtant le chéquier.